Dec 1, 1977

Bleomycin-sensitivity test: application for human squamous cell carcinoma

Cancer
W E MüllerH Scheunemann

Abstract

Bleomycin (BLM)-inactivating enzyme activity, which is probably a parameter for the efficacy of this antibiotic in cancer therapy, was determined in biopsies from human carcinomas in the head and neck region. Twenty-three cases were studied. It was found that highly differentiated as well as moderately differentiated squamous cell carcinomas had low extractable activities of this enzyme, comparably to those found in normal skin tissue. Slightly differentiated as well as undifferentiated carcinomas (only one case) had increased enzyme activity. Parallel experiments estimating the total extractable thiol content in the biopsies gave no obvious correlation. The results are discussed in the light of the reported BLM efficacy in the treatment of differently differentiated squamous cell carcinomas.

  • References5
  • Citations5

References

Mentioned in this Paper

Skin Tissue
Undifferentiated Carcinoma
Sulfhydryl Compounds
Bleomycin
Cell Differentiation Process
Head and Neck Structure
Enzyme Activity
Blood Enzyme Activity (Lab Test)
Squamous Cell Carcinoma
Biopsy

About this Paper

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
F C IzsakC Raanani
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
J N LickissA G Baikie
Cancer Chemotherapy and Pharmacology
B I Sikic, R L Taber
© 2020 Meta ULC. All rights reserved